Lacosamide Zydus

Lacosamide, the active ingredient in Lacosamide Zydus, is an anti‑epileptic presented as an oral tablet for oral use. It is employed as adjunctive therapy for partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic drug used to manage seizure disorders, particularly focal seizure activity.

- Partial‑onset seizures: reduces seizure frequency when added to existing therapy. - Focal seizures: improves overall seizure control in patients with refractory epilepsy. - Adjunctive therapy in epilepsy: used when monotherapy does not achieve adequate seizure suppression.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate pain in the head region. - Fatigue: increased tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal ideation: thoughts of self‑harm requiring immediate medical attention. - Severe skin rash: including Stevens‑Johnson syndrome. - Cardiac arrhythmia: abnormal heart rhythm, especially in patients with pre‑existing conduction disorders. - Hypersensitivity reactions: such as angioedema or anaphylaxis. - Blood dyscrasias: rare cases of agranulocytosis or aplastic anemia.

When prescribing Lacosamide, clinicians should consider several safety aspects.

- Renal impairment: adjust dosing in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy: safety not established; weigh benefits against potential risks. - Store below 25°C: keep in the original pack, protect from moisture.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): may reduce Lacosamide plasma levels. - Other sodium‑channel blockers (e.g., oxcarbazepine): increased risk of CNS depression. - Concomitant use with beta‑blockers: may exacerbate cardiac conduction effects.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole): may increase Lacosamide exposure. - Alcohol: additive central nervous system depression. - Other antiepileptic drugs (e.g., valproate): monitor seizure control and side‑effect profile.